These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 773583)

  • 1. Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis.
    Ellard GA
    Clin Pharmacol Ther; 1976 May; 19(5 Pt 2):610-25. PubMed ID: 773583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis].
    Ellard GA
    Rev Mal Respir; 1984; 1(4):207-19. PubMed ID: 6505358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acetylator phenotyping of tuberculosis patients using matrix isoniazid or sulphadimidine and its prognostic significance for treatment with several intermittent isoniazid-containing regimens.
    Ellard GA; Gammon PT
    Br J Clin Pharmacol; 1977 Feb; 4(1):5-14. PubMed ID: 843424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis.
    Gurumurthy P; Krishnamurthy MS; Nazareth O; Parthasarathy R; Sarma GR; Somasundaram PR; Tripathy SP; Ellard GA
    Am Rev Respir Dis; 1984 Jan; 129(1):58-61. PubMed ID: 6367570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between serum and urinary sulphadimidine acetylation as predictors of isoniazid acetylator status in patients with pulmonary tuberculosis.
    Singh SP; Pande JN; Khilnani GC; Kailash S
    Indian J Chest Dis Allied Sci; 1996; 38(1):5-11. PubMed ID: 16892742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
    Clark DW
    Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acetylator phenotyping with sulphadimidine in patients receiving isoniazid.
    Ylitalo P; Auterinen L; Marttinen A; Koivula T
    Int J Clin Pharmacol Res; 1984; 4(2):141-4. PubMed ID: 6469440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isoniazid acetylation rates (phenotypes) of patients being treated for tuberculosis.
    Mason E; Russell DW
    Bull World Health Organ; 1971; 45(5):617-24. PubMed ID: 5316954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of the acetylator phenotype using matrix isoniazid.
    Ellard GA; Gammon PT; Titinen H
    Tubercle; 1975 Sep; 56(3):203-9. PubMed ID: 1216339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of isoniazid acetylation phenotypes in North Indians.
    Gupta RC; Nair CR; Jindal SK; Malik SK
    Int J Clin Pharmacol Ther Toxicol; 1984 May; 22(5):259-64. PubMed ID: 6746149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Isoniazid acetylation in a group of Tunisian patients. Report of 620 patients].
    Mehiri BR; Zouaoui A; Chérif J; Ourari B; Daghfous R; Oueslati MH; Louzir B; Daghfous J; Chelbi B; Béji M
    Tunis Med; 2005 Jul; 83(7):385-9. PubMed ID: 16220693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis.
    Ellard GA
    Tubercle; 1984 Sep; 65(3):211-27. PubMed ID: 6385429
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical pharmacokinetics of isoniazid.
    Weber WW; Hein DW
    Clin Pharmacokinet; 1979; 4(6):401-22. PubMed ID: 391461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The importance of estimating the individual acetylation rate in modern tuberculosis treatment].
    Duru S
    Mikrobiyol Bul; 1979 Jan; 13(1):53-61. PubMed ID: 555792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Type of isoniazid (INH) acetylation determined in tuberculosis patients treated at the Institute of Tuberculosis and Lung Diseases in Warsaw during the years 1990-1997].
    Augustynowicz-Kopeć E; Zwolska Z
    Pneumonol Alergol Pol; 2002; 70(3-4):180-92. PubMed ID: 12271965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled trial of intermittent regimens of rifampicin plus isoniazid for pulmonary tuberculosis in Singapore.
    Lancet; 1975 Dec; 2(7945):1105-9. PubMed ID: 53598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype.
    Yamamoto T; Suou T; Hirayama C
    Hepatology; 1986; 6(2):295-8. PubMed ID: 3957235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy.
    Cordes H; Thiel C; Aschmann HE; Baier V; Blank LM; Kuepfer L
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6134-45. PubMed ID: 27480867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Acetylation phenotype of isoniazid in Morocco. Preliminary study of 100 cases].
    Bouayad Z; Chevalier B; Maurin R; Bartal M
    Rev Fr Mal Respir; 1982; 10(6):401-7. PubMed ID: 7163595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of various isoniazid slow releasing matrix preparations for intermittent chemotherapy of tuberculosis.
    Hodgkin MM; Eidus L; Hershfield ES
    Res Commun Chem Pathol Pharmacol; 1979 May; 24(2):349-65. PubMed ID: 461989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.